Karyopharm Expanded Access Program for Selinexor

NCT07215832 | Unknown

• 1 other identifier: KEAP-KPT-330
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is commercially available in the country. Patients who do not qualify for an ongoing clinical trial but who might benefit from the investigational medicine may be eligible, provided they have exhausted all other available treatment options. Investigational medicines are provided to patients only through treating physicians who obtain the relevant approval on behalf of their patient from the relevant regulatory agency and follow all applicable safety-reporting regulations of the respective country.

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL); Multiple Myeloma; Sarcoma; Neuroglioblastoma; Peripheral T-cell Lymphoma; Endometrial Cancer; Myelofibrosis; Other

Keywords

selinexor

Interventions

selinexor DRUG

KPT-330

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Sponsors & Collaborators

• Karyopharm Therapeutics Inc: lead
• Caligor Coghlan (CalCog): collaborator

MeSH Terms

Conditions

Multiple Myeloma; Lymphoma, Large B-Cell, Diffuse; Sarcoma; Lymphoma, T-Cell, Peripheral; Endometrial Neoplasms; Primary Myelofibrosis

Interventions

selinexor

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Lymphatic Diseases; Neoplasms, Connective and Soft Tissue; Lymphoma, T-Cell; Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Myeloproliferative Disorders; Bone Marrow Diseases

Central Study Contacts

Karyopharm Medical Information

CONTACT

(888) 209-9326; keap.admin@karyopharm.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 30, 2025
• First Posted: October 14, 2025
• Last Updated: March 2, 2026

Record last verified: 2026-02